METHODS: 108 male volunteers with LUTS defined as International prostate symptom score over 8 were screened. Electrocardiographic signals were obtained from subjects in resting state for the analysis of their HRV. HRV parameters were analyzed to evaluate autonomic functions. We divided them into two groups by LF/HF ratio 1.6 after initial measurement. After the administration of alfuzosin 10mg once a day for 12 weeks, we evaluated HRV to investigate changes of autonomic functions. RESULTS: Total 95 LUTS patients who completed this study were enrolled. 54 subjects with LF/HF ratio under or equal 1.6 were allocated to group A and 41 patients with LF/HF ratio over 1.6 were allocated to group B. There were no statistical differences in serum PSA, volume of prostate, maximal urine flow rate between two groups. There was no statistical difference in improvement of peak urine flow rate, IPSS after treatment with alfuzosin 10mg for 12 weeks. The average LF/HF ratio of group A was increased from 0.89 AE 0.40 to 1.79 AE 1.80, however it was decreased from 3.93 AE 5.47 to 1.79 AE 1.15 in group B.
INTRODUCTION AND OBJECTIVES:
Benign Prostate Hyperplasia (BPH) is a major cause of Lower Urinary Tract Symptoms (LUTS) in men and surgical treatment is often required. However, due to long terms of difficulty, some patients show very weak detrusor functions. The aim of this study is to determine risk factors of low detrusor function.
METHODS: We retrospectively reviewed 345 patients who were clinically diagnosed as BPH and videourodynamic studies (V-UDSs) was performed between 2008 and 2016. Age, prostate volume, post-voided residual urine (PRV) were evaluated. As the UDS parameters, mean bladder compliance, mean abdominal leak point pressure, Qmax, and Pdetmax were evaluated. The Schafer 0 s nomogram was used to evaluate the obstruction of lower urinary tract. The correlations among age, prostate volume, and V-UDSs findings were evaluated to determine the causal factor of weak detrusor function. The results of V-UDSs were compared among the groups. Spearman's rank correlation coefficient was used to evaluate the correlations. UDS findings were compared among the divided groups using unpaired t-tests.
RESULTS: The mean value of prostate volume was 39ml. Mean PVR was 97ml and 102 patients had more than 100ml of PVR. During the filling phase 79 patients had detrusor overactivity (DO). 70 patients showed decrease in urinary sensation. As the result of Schafer's nomogram, 254 patients had a stronger obstruction than grade 3 and 102 patients had a lower detrusor function than weak. Patients who had DO had a tendency of weak detrusor. Although the values of age and prostate volume did not show a correlation with UDSs findings including obstruction and weak detrusor, age and detrusor, prostate volume and obstruction showed a correlation (Fig 1) . Compared by age, 78 years old was a cut off of weak detrusor (Fig 2.3) .
CONCLUSIONS: From this study, high age and the presence of DO was a risk factor for weaker detrusor. Elderly who have DO may need surgical treatment in an early stage. Peter Rosier*, Utrecht, Netherlands INTRODUCTION AND OBJECTIVES: Initial management of LUTS in elderly male may be pragmatic with lifestyle management and medication. This is frequently successful however when the patients are still symptomatic and or worried about the safety of this initial treatment it might be useful to be able to estimate the likelihood of serious bladder outflow obstruction (BOO). With the hypothesis that patients with higher grade of outflow obstruction are more likely to fail conservative (& pharmaco-therapeutic) management we tested whether clinical of symptom parameters were suitable to predict moderate and high grade BOO (hgBOO) in the elderly male patients. METHODS: 452 elderly male patients referred with LUTS had IPSS, flowmetry (Q max ) and transrectal ultrasound prostate volume measurement (TRUS). Mean age (sd) was 64.8y (11.2) Q max 11.8mL/s (6.6) and TRUS 41.7cm 3 (23.9). All patients underwent standard cystometry and pressure flow analysis. A cut off URA value of 40cmH 2 O was taken for hgBOO (similar¼: linPURR>3) RESULTS: ROC curve showed that TRUS and Q max were better than IPSS to diagnose hgBOO and the combination of these to into CLIPS (TRUS-3*Q max ) further increased the diagnostic power, with ROC area .76.(Note that Q max projects negative because a higher value is 'better') CONCLUSIONS: CLInical Prostate Score¼ (prostate volume -3*Q max ) is a far better predictor of high grade BOO than totalIPSSscore. METHODS: A consecutive series of patients with LUTS and Benign prostatic enlargement (BPE) underwent TURP in our center in 2004-2005 and they were then followed up to 2016. Patients were assessed at baseline, 3-, 6-months post-operatively and yearly thereafter with medical history (concomitant medication, reintervention), IPSS, PSA, prostate volume, maximal urinary flow rate (Qmax), post void residual urine (PVR). Reoperation was defined as the requirement of a new TURP to relieve bothersome LUTS. Multivariate logistic regression was used to determine covariates associated with reoperation rate and the Kaplan-Meier curve assessed the time to reoperation. RESULTS: Overall 92 patients were enrolled. Mean age was 79 AE 7 years; mean PSA was 3.2 AE 2.5 ng/ml; mean TRUS volume was 57.5 AE 18.6 ml; mean Qmax was 8.7 AE 4 ml/s; mean IPPS was 23 AE 6 respectively at baseline. Mean follow-up was 140 AE 8 months (median 142 months). Overall 20/92 (21.7%) patients received medical treatment (alpha-blockers and/or 5 alpha-reductase inhibitors) after TURP. 13 patients underwent re-TURP during follow-up (reoperation rate was 14%); out of them 9/13 (69%) received medical treatment for persistent LUTS, while the remaining 4 patients received no additional pharmacological treatment (p ¼ 0.001). Out of the 13 patients treated with re-TURP, 12 (92%) underwent surgery within 5 years of follow-up. Median time to reintervention was 26 months, interquartile range 14/46. The need of LUTS/BPE pharmacological treatment after TURP is an independent risk factor for re-intervention (Odds Ratio 13.93; 95% Confidence Interval 3.63-53.48, p¼ 0.000). Cumulative re-TURP free probability, according to post-operative continuing medical treatment, is showed in Figure 1 . CONCLUSIONS: In our study, a small number of patients (21.7%) still required pharmacological treatment for persistent LUTS. This need was a predictive factor of a re-TURP. Considering that more that 90% of re-TURP were performed during the first 5 years of followup, it is assumable that a follow-up longer than 5 years is not needed in such group of patients.
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MP13-07 FINASTERIDE MONOTHERAPY BEFORE TURP: SIGNIFICANT IMPROVEMENT IN EARLY POSTOPERATIVE QUALITY OF LIFE
Ahmed Ali*, Emad Ramadan, Mamdouh El-Hawy, tarek fathelbab, Alayman Hussein, Minia, Egypt; Luay Alshara, Boston, MA; Ahmed Fawzy, Ehab Tawfiek, Minia, Egypt INTRODUCTION AND OBJECTIVES: Introduction: Benign prostatic hyperplasia (BPH) is a common disease affecting men 50 years and older. Treatment options consist of observation, pharmacological treatment, minimally invasive surgery and traditional surgery. Alpha-blockers and 5-alpha-reductase inhibitors are the primary medications used to treat BPH. Transurethral resection of the prostate (TURP) is the gold standard of surgical management of BPH. We sought to evaluate the effect of six weeks of finasteride therapy before TURP on overall surgical outcomes and early postoperative quality of life (QoL).
METHODS: Between June 2011 and August 2013, patients with BPH at the urology department, Minia University Hospital, were randomly assigned to one of two groups: those receiving 5 mg of Finasteride daily for six weeks (group A) and those not receiving finasteride (group B) before TURP. All patients were assessed using a modified validated Arabic version of the International Prostate Symptom Score (IPSS). Intra operative serum hemoglobin concentration and hemoglobin concentration in irrigating fluid were recorded. On the first postoperative day, serum hemoglobin concentration, corrected by postoperative hematocrit values, was evaluated. One month post-surgery, IPSS, storage and voiding subscores and QoL scores were measured. RESULTS: We recruited 115 patients, of whom 98 completed the study. Before surgery, there was no significant difference between the two groups in prostate size, IPSS, maximum urinary flow rate, postvoid residual urine test results or QoL scores. Group A patients had significantly less intraoperative blood loss than group B patients (p¼ 0.001). One month postoperatively, there was no significant difference in IPSS results or voiding and storage subscores between the two groups. However, group A patients showed greater improvement in QoL than group B patients (p ¼ 0.03).
CONCLUSIONS: Short-term finasteride therapy for 6 weeks before TURP reduced intraoperative blood loss and improved quality of life in the early postoperative period.
